• Vaccine Name: T. gondii DNA vaccine pSAG1-ROP2-SAG2
• Target Pathogen: Toxoplasma gondii
• Target Disease: Toxoplasmosis
• Vaccine Ontology ID: VO_0004312
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• p30 gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
  • Detailed Gene Information: Click Here.
• SAG2 gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
  • Detailed Gene Information: Click Here.
• ROP2 gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid: pcDNA3.1 DNA vaccine plasmid
  • DNA vaccine plasmid name: pcDNA3.1 DNA vaccine plasmid
  • DNA vaccine plasmid VO ID: VO_0000158
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Six groups (14 per group) of mice were injected intramuscularly (50 µL in each thigh skeletal muscle) with 100 µg of plasmid DNA suspended in 100 µL sterile PBS. Group I was injected with PBS as control, group II with pcDNA3·1 vector alone as control, group III with pSAG2, group IV with pSAG1-ROP2, group V with pSAG1-ROP2-SAG2 and group VI with pSAG1-ROP2-SAG2 + pIL-12 (100 µg each). The mice were immunized on days 0, 14 and 28 with the same protocol. (Cui et al., 2008)
• Vaccine Immune Response Type: VO_0000286
• Challenge Protocol: On day 56, seven immunized mice per group were challenged with 10^4 tachyzoites of the T. gondii RH strain. The survival days of the mice was recorded. (Cui et al., 2008)
• Efficacy: Higher survival rates after lethal challenge were obtained in mice immunized with pSAG1-ROP2-SAG2 as compared to the mice immunized with PBS, expression vector alone or pSAG2, or pSAG1-ROP2. In addition, the protection induced by pSAG1-ROP2-SAG2 was remarkably enhanced by pIL-12 co-administration (Cui et al., 2008).